Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Irinotecan in Recurrent or Refractory Sarcomas
NCT01380275Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2008
- Primary completion
- Sep 2014
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in sarcoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
docetaxelirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT01380275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01380275.